Cruz Ricardo, Wuest William M
Department of Chemistry, Emory University, 1515 Dickey Dr. Atlanta GA 30322.
Tetrahedron. 2023 Mar 3;133. doi: 10.1016/j.tet.2023.133268. Epub 2023 Jan 11.
and are historically problematic fungal pathogens responsible for systemic infections and high mortality rates, especially in immunocompromised populations. The three antifungal classes that comprise our present day armamentarium have facilitated efficacious treatment of these fungal infections in past decades, but their potency has steadily declined over the years as resistance to these compounds has accumulated. Importantly, pan-resistant strains of have been observed in clinical settings, leaving affected patients with no treatment options and a death sentence. Many compounds in the ongoing antifungal drug discovery pipeline, similar to those within our aforementioned trinity, are predicated on the binding or inhibition of ergosterol. Recurring accounts of resistance to antifungals targeting this pathway suggest optimization of ergosterol-dependent antifungals is likely not the best solution for the long-term. This review aims to present several natural products with novel or underexplored biological targets, as well as similarly underutilized drug discovery strategies to inspire future biological investigations and medicinal chemistry campaigns.
[具体真菌名称1]和[具体真菌名称2]是历史上存在问题的真菌病原体,可导致全身感染和高死亡率,尤其是在免疫功能低下的人群中。构成我们目前抗真菌药物库的三类抗真菌药物在过去几十年中促进了对这些真菌感染的有效治疗,但随着对这些化合物的耐药性不断积累,它们的效力多年来一直在稳步下降。重要的是,在临床环境中已观察到[具体真菌名称1]的全耐药菌株,使受影响的患者没有治疗选择,只能面临死亡。正在进行的抗真菌药物研发管道中的许多化合物,与上述三种药物类似,都是基于对麦角甾醇的结合或抑制。针对该途径的抗真菌药物耐药性的反复报道表明,优化依赖麦角甾醇的抗真菌药物可能不是长期的最佳解决方案。本综述旨在介绍几种具有新颖或未充分探索的生物学靶点的天然产物,以及同样未充分利用的药物发现策略,以激发未来的生物学研究和药物化学研究。